A wearable sensor is being used to study cancer-related fatigue in patients with breast cancer

Breast cancer-related fatigue to be studied with wearable sensor

A team of researchers from Letterkenny Institute of Technology (LYIT) and Letterkenny University Hospital (LUH) is to use Shimmer’s Verisense™ continuous monitoring platform to...
Science technology equipment: Nick Gabelle is a Multi-Channel Key Account Manager for Star, working with a client on the launch of their new treatment for Type 2 diabetes

Shionogi reports positive results for cefiderocol in adults with pneumonia

Shionogi announce results from APEKS-NP, an international, Phase III clinical trial for cefiderocol in adults with pneumonia.   This trial evaluated the efficacy and safety of...

Health Secretary Matt Hancock opens Sanofi’s new UK headquarters

Sanofi has officially opened its new UK headquarters at Four 10, Thames Valley Park (TVP) in Reading, Berkshire. Sanofi UK welcomed the Rt Hon Matt...
AstraZeneca presents results from Phase III TULIP 2 trial for anifrolumab

Novartis shares Cosentyx® treatment results data

Novartis has announced results for Cosentyx from a pooled-analysis that shows sustained improvement in signs and symptoms of psoriatic arthritis, particularly for American College...
Image of lungs to show Research into early signs of lung cancer spread

Research into early signs of lung cancer spread

Early signs of lung cancer spread and that it may become untreatable can be picked up in samples of blood and tumour, according to...
SMC rejects breast cancer drug Perjeta for use post-surgery

SMC rejects breast cancer drug Perjeta®(pertuzumab) for use post-surgery

The Scottish Medicine Consortium (SMC) has rejected the use of pertuzumab for use in combination with trastuzumab and chemotherapy for the adjuvant treatment of...
Scottish flag showing Novartis advanced breast cancer treatment approved in Scotland

NHS Scotland accepts AbbVie’s SKYRIZI™▼ (risankizumab)

NHS Scotland accepts AbbVie’s SKYRIZI™ (risankizumab) in a positive Detailed Advice Document published by the Scottish Medicine Consortium. It confirms that SKYRIZI™▼(risankizumab) is recommended for...
MS Society launches public appeal to raise £100 million to stop multiple sclerosis

MS Society launches fundraising appeal to stop multiple sclerosis

The MS Society has launched a hard-hitting public appeal to raise £100 million to stop multiple sclerosis (MS). The campaign features adverts showing real...
Man and woman shaking hands to show new development in CMA illegal market sharing investigation

New development in CMA illegal market sharing investigation

Three drug firms have been accused of illegal market sharing and the CMA has provisionally found that the companies signed an illegal agreement that...
Image of a woman undergoing medical examination highlighting Tecentriq by Roche not approved on NHS for triple negative breast cancer

Tecentriq by Roche not approved on NHS for triple negative breast cancer

Draft guidance published by NICE does not recommend atezolizumab, Tecentriq by Roche, for treating people with a type of breast cancer that has spread...

Latest articles

Image of four people communicating via different mediums to depict mind the Generation Gap in pharma marketing

Mind the Generation Gap in pharma marketing and market research

Industry came together to explore the impact of the generation gap in pharma marketing and market research at BHBIA's summer event. Different generations have always...
AstraZeneca presents results from Phase III TULIP 2 trial for anifrolumab

AstraZeneca presents anifrolumab results from Phase III TULIP trial

Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Scottish flag showing Novartis advanced breast cancer treatment approved in Scotland

Novartis advanced breast cancer treatment approved in Scotland

Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...

Popular articles

People sitting around a desk with laptops and tablets to show NHS Commercial Framework for Medicines published for consultation

NHS Commercial Framework for Medicines consultation published

NHS England has published the NHS Commercial Framework for Medicines for consultation. NHS England has a significant role to play in supporting patient access to...
Mapping NHS change is key to customer engagement

Mapping NHS change is key to customer engagement

Simon Grime, of Wilmington Healthcare, explains how mapping NHS change through data and intelligence can help industry understand and engage customers in the new...
Pharmafield logo in lightbulb: Pf Power List 2019

Pf Power List 2019: Who is shaping the pharma & healthcare sector?

The Pf Power List has looked at who is making a difference in pharma and healthcare in 2019. This year has brought a range of developments...
Scottish flag showing Novartis advanced breast cancer treatment approved in Scotland

Novartis advanced breast cancer treatment approved in Scotland

Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...
Image of a head with squiggly lines in the brain and cogs on top to indicate Medopad and Janssen collaborate on novel digital biomarker for Alzheimer's disease

Medopad and Janssen collaborate on novel digital biomarker for Alzheimer’s disease

Medopad has announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription